Overview


According to FutureWise analysis, the market for Aneurysmal Subarachnoid Hemorrhage Drugs is estimated to be US$ 0.36 billion in 2023 and is expected to reach US$ 0.49 billion by 2031 at a CAGR of 3.8% over the forecast period of 2023-2031.

Subarachnoid hemorrhage (SAH) is a critical medical condition characterized by bleeding in the space between the brain and the protective membranes covering it, known as meninges. SAH specifically occurs when bleeding takes place beneath the arachnoid layer. There are several causes of SAH, the most common being head trauma and a brain aneurysm rupture. The severity of SAH can vary, and it is crucial to recognize that SAH is a medical emergency. The primary and often most prominent symptom of SAH is a thunderclap headache, an excruciatingly painful headache that comes on suddenly, likened to the sudden clap of thunder. Those who experience a thunderclap headache often describe it as the most severe headache they have ever encountered, unlike any previous headache they may have had. SAH includes a range of symptoms, including decreased consciousness and alertness, nausea and vomiting, a stiff neck, sudden weakness, mood and personality changes (such as confusion and irritability), dizziness, eye sensitivity in bright light (photophobia), muscle aches (especially in the neck and shoulders), numbness in parts of the body, seizures, and vision changes. The life-threatening nature of SAH requires immediate treatment in a hospital's intensive care unit (ICU), typically with specialized neurological expertise. The treatment objectives are to save the patient's life, address the source of bleeding, alleviate symptoms, and prevent potential complications like vasospasm, hydrocephalus, and permanent brain damage.

Treatment measures may include life support to relieve pressure in the brain, a draining tube, airway protection methods, medications to reduce intracranial swelling and manage blood pressure, drugs to prevent artery spasms (vasospasms), pain relief, anti-anxiety medications, and seizure prevention or management. Surgical interventions may be necessary to remove significant blood accumulations, repair the aneurysm responsible for the SAH, or address other specific causes, especially in head trauma cases.

FutureWise Market Research has published a report that provides an insightful analysis of Aneurysmal Subarachnoid Hemorrhage Drugs Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that Aneurysmal Subarachnoid Hemorrhage Drugs Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Arbor Pharmaceuticals
  • Edge Therapeutics
  • Johnson & Johnson
  • Mylan N.V
  • Orexo AB
  • Pfizer
  • Purdue Pharma
  • Pharmaxis'
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical

(Note: The list of the major players will be updated with the latest market scenario and trends)

Major drivers for the market growth are the upsurge in the prevalence of diseases like hypertension and stroke, fostering market growth. Ever-rising technological advancements and innovations are also a growth factor. The increasing recognition of the advantages of minimally invasive procedures is fuelling the market's expansion. Growing awareness about aneurysmal Subarachnoid Hemorrhage and proactive screening initiatives lead to early detection and treatment, contributing to market expansion. Also, consumption of alcohol and increased smoking raise the increased risk of Aneurysmal Subarachnoid Hemorrhage. Improved imaging techniques such as CT angiography and magnetic resonance angiography help in early and precise diagnosis, enabling the cure in time and patient safety, thus propelling the market growth. The government is organizing awareness programs, and non-government organizations are helping people become more knowledgeable about the disease and its treatment modalities, fuelling the market growth.  
 
However, the market is affected by significant restraints, such as a need for more awareness in underdeveloped nations. Also, the lack of qualified and skilled medical professionals hampers market growth as they are not readily available everywhere and are limited to the big cities. High cost is a significant restraint for this market as the surgical procedures are very costly and hence are less affordable to the lower socioeconomic strata of the population, thus hampering the market growth. Invasive procedures carry some risks and complications that may make people ignorant of the methods and are declining the market growth.

By Product Type

  • Opioid Analgesic
  • Calcium Channel Blocker
  • Anticonvulsant
  • Stool Softener
  • Osmotic Agent
  • Other Drugs

By Applications

  • Hospitals
  • Clinics
  • Homecare

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process. 

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America holds the largest market share due to the well-established health infrastructure, early adoption of technological advancements, high healthcare expenditure, adoption of minimally invasive procedures, and growing prevalence of hypertensions and strokes. Whereas Asia-Pacific is a rapidly growing market due to the majority of increasing public awareness about aneurysms, expanded access to healthcare services and improvised healthcare infrastructure are propelling the market growth in this region. In addition, government initiatives are playing a significant role in raising funds and promoting advanced healthcare technologies.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the of Aneurysmal Subarachnoid Hemorrhage Drugs Market By Product Type, By Application and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represents in format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Aneurysmal Subarachnoid Hemorrhage Drugs Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Aneurysmal Subarachnoid Hemorrhage Drugs Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Opioid Analgesic
        2. Calcium Channel Blocker
        3. Anticonvulsant
        4. Stool Softener
        5. Osmotic Agent
        6. Other Drugs

  • 8.   Global Aneurysmal Subarachnoid Hemorrhage Drugs Market, By Applications Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Clinics
        3. Homecare

  • 9.   North America Aneurysmal Subarachnoid Hemorrhage Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Arbor Pharmaceuticals
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Edge Therapeutics
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Johnson
      Johnson
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
         4. Mylan N.V
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Orexo AB
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Pfizer
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Purdue Pharma
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Pharmaxis'
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Sun Pharmaceutical Industries
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.Teva Pharmaceutical
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients